Immunotherapy in renal cell carcinoma

Immunotherapy

Volumn 1, Issue 1, 2009, Pages 97-107

  Heine, Annkristin ^a   Holderried, Tobias A W ^a   Brossart, Peter ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cancer vaccine; Clinical trial; Dendritic cell; Immunotherapy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RNA VACCINE; VASCULOTROPIN;

ADOPTIVE TRANSFER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; TOR SERINE-THREONINE KINASES; VACCINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953385011     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.1.97     Document Type: Review

References (79)

1. Rini BI: VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 10, 191-197 (2005).
2. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996). ■■ Excellent overview on renal cell carcinoma covering epidemiology, diagnostic and treatment options.
3. Glaspy JA: Therapeutic options in the management of renal cell carcinoma. Semin. Oncol. 29, 41-46 (2002).
4. Belldegrun A, Muul LM, Rosenberg SA: Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and anti tumor activity. Cancer Res. 48, 206-214 (1988). (Pubitemid 18030352)
5. Thurnher M, Radmayr C, Ramoner R et al.: Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer 68, 1-7 (1996). (Pubitemid 26354569)
6. Hernberg M, Pyrhonen S, Muhonen T: Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J. Immunother. 22, 145-154 (1999). (Pubitemid 29135899)
7. Nathan PD, Eisen TG: The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol. 3, 89-96 (2002).
8. Atzpodien J, Kirchner H, Jonas U et al.: Interleukin-2- and interferon α-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 22, 1188-1194 (2004). (Pubitemid 41079830)
9. Ratain MJ, Eisen T, Stadler WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
10. Motzer RJ, Michaelson MD, Redman BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
11. Yang JC, Haworth L, Sherry RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
12. Hudes G, Carducci M, Tomczak P et al.: Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
13. Atkins MB, Hidalgo M, Stadler WM et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
14. Escudier B, Pluzanska A, Koralewski P et al.: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet. 370, 2103-2111 (2007). (Pubitemid 350296300)
15. Tykodi SS, Warren EH, Thompson JA et al.: Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 10, 7799-7811 (2004).
16. Hentschke P, Barkholt L, Uzunel M et al.: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31, 253-261 (2003). (Pubitemid 36336227)
17. Childs R, Chernoff A, Contentin N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
18. Rini BI, Zimmerman T, Stadler WM et al.: Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol. 20, 2017-2024 (2002).
19. Bregni M, Dodero A, Peccatori J et al.: Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99, 4234-4236 (2002). (Pubitemid 35332074)
20. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392, 245-252 (1998). ■■ Eessential paper on the functions of dendritic cells.
21. Cella M, Engering A, Pinet V et al.: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782-787 (1997). (Pubitemid 27375158)
22. Reichardt VL, Brossart P, Kanz L: Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 18, 235-243 (2004). (Pubitemid 39388888)
23. Nencioni A, Brossart P: Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 22, 501-513 (2004). ■ Describes in detail various options of vaccination therapies.
24. Marten A, Renoth S, Heinicke T et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 14, 483-494 (2003).
25. Su Z, Dannull J, Heiser A et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63, 2127-2133 (2003). (Pubitemid 36538616)
26. Holtl L, Zelle-Rieser C, Gander H et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8, 3369-3376 (2002).
27. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al.: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase 1 study. J. Immunother. 25, 500-508 (2002).
28. Wierecky J, Muller MR, Wirths S et al.: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66, 5910-5918 (2006). (Pubitemid 43927146)
29. Holtl L, Rieser C, Papesh C et al.: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 161, 777-782 (1999). (Pubitemid 29422365)
30. Jocham D, Richter A, Hoffmann L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363, 594-599 (2004). (Pubitemid 38264176)
31. Gong J, Chen D, Kashiwaba M et al.: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3, 558-561 (1997).
32. Avigan DE, Vasir B, George DJ et al.: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30, 749-761 (2007). (Pubitemid 47480758)
33. Heiser A, Maurice MA, Yancey DR et al.: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 61, 3388-3393 (2001). (Pubitemid 32695030)
34. Grunebach F, Muller MR, Nencioni A et al.: Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther. 10, 367-374 (2003). (Pubitemid 36372444)
35. Gilkeson GS, Pippen AM, Pisetsky DS: Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J. Clin. Invest. 95, 1398-1402 (1995).
36. Hoerr I, Obst R, Rammensee HG et al.: In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30, 1-7 (2000).
37. Donnelly J, Berry K, Ulmer JB: Technical and regulatory hurdles for DNA vaccines. Int. J. Parasitol. 33, 457-467 (2003).
38. Klinman DM, Takeno M, Ichino M et al.: DNA vaccines: safety and efficacy issues. Springer Semin. Immunopathol. 19, 245-256 (1997).
39. Carralot JP, Probst J, Hoerr I et al.: Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol. Life Sci. 61, 2418-2424 (2004).
40. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June, 2008.
41. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
42. Jameson SC: Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2, 547-556 (2002).
43. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24, 5060-5069 (2006).
44. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June, 2008.
45. Koike N, Pilon-Thomas S, Mule JJ: Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J. Immunother. 31, 402-412 (2008). (Pubitemid 351595163)
46. Dunn GP, Bruce AT, Ikeda H et al.: Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
47. Woo EY, Yeh H, Chu CS et al.: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276 (2002). (Pubitemid 34441324)
48. Curiel TJ, Coukos G, Zou L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
49. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
50. Onizuka S, Tawara I, Shimizu J et al.: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128-3133 (1999).
51. Olsen E, Duvic M, Frankel A et al.: Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376-388 (2001).
52. Dannull J, Su Z, Rizzieri D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633 (2005).
53. Powell DJ Jr, Felipe-Silva A, Merino MJ et al.: Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 179, 4919-4928 (2007).
54. Kristiansen OP, Larsen ZM, Pociot F: CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun. 1, 170-184 (2000).
55. Tivol EA, Borriello F, Schweitzer AN et al.: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
56. Waterhouse P, Penninger JM, Timms E et al.: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985-988 (1995).
57. Ribas A, Camacho LH, Lopez-Berestein G et al.: Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23, 8968-8977 (2005).
58. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832 (2001).
59. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484 (2006).
60. Pashenkov M, Goess G, Wagner C et al.: Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24, 5716-5724 (2006).
61. West MA, Wallin RP, Matthews SP et al.: Enhanced dendritic cell antigen capture via Toll-like receptor-induced actin remodeling. Science 305, 1153-1157 (2004).
62. Hofmann MA, Kors C, Audring H et al.: Phase I evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 31, 520-527 (2008).
63. + T-cell reactivity in melanoma patients. Clin. Cancer Res. 14, 4532-4542 (2008).
64. Bargou R, Leo E, Zugmaier G et al.: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977 (2008). ■ Interesting new approach that might have essential impact on future immunotherapy.
65. Hoffmann P, Hofmeister R, Brischwein K et al.: Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98-104 (2005). (Pubitemid 40559673)
66. Brischwein K, Parr L, Pflanz S et al.: Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30, 798-807 (2007). (Pubitemid 350295358)
67. Dreier T, Baeuerle PA, Fichtner I et al.: T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J. Immunol. 170, 4397-4402 (2003). (Pubitemid 36428210)
68. Schlereth B, Fichtner I, Lorenczewski G et al.: Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res. 65, 2882-2889 (2005). (Pubitemid 40490092)
69. Schlereth B, Kleindienst P, Fichtner I et al.: Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for murine CD3. Cancer Immunol. Immunother. 55, 785-796 (2006).
70. Brischwein K, Schlereth B, Guller B et al.: MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43, 1129-1143 (2006).
71. Hammond SA, Lutterbuese R, Roff S et al.: Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res. 67, 3927-3935 (2007). (Pubitemid 46762182)
72. Offner S, Hofmeister R, Romaniuk A et al.: Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763-771 (2006).
73. Bui MH, Seligson D, Han KR et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
74. Uemura H, Nakagawa Y, Yoshida K et al.: MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer. 81, 741-746 (1999).
75. Davis ID, Wiseman GA, Lee FT et al.: A Phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 7, 13 (2007).
76. Davis ID, Liu Z, Saunders W et al.: A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun. 7, 14 (2007).
77. Bleumer I, Knuth A, Oosterwijk E et al.: A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90, 985-990 (2004). (Pubitemid 38495816)
78. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
79. Hipp MM, Hilf N, Walter S et al.: Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111, 5610-5620 (2008).